CD20 has proven to be an excellent target for the treatment of B-cell lymphoma (1) and investigations for treatment of NHL have been based on the development of antibody against CD20 antigens (2). This evidence concerns the gene MS4A1 and B-cell non-Hodgkin lymphoma.